Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1980 Mar;77(3):1706–1710. doi: 10.1073/pnas.77.3.1706

Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2.

A M Lefer, E F Smith 3rd, H Araki, J B Smith, D Aharony, D A Claremon, R L Magolda, K C Nicolaou
PMCID: PMC348566  PMID: 6929517

Abstract

Carbocyclic thromboxane A2 [2 beta (Z),3 alpha- (1E,3R*)-3-(3-hydroxy(1-octenyl)-bicyclo[3.1.1]hept-2-yl-5-heptenoic acid], a stable analog of thromboxane A2, has been tested for its physiologic properties. Carbocyclic thromboxane A2 is a potent coronary vasoconstrictor, stimulating cornonary vascular smooth muscle at concentrations as low as 29 pM. At 1-5 micro M it is also an inhibitor of arachidonic-acid- and endoperoxide-induced aggregation of platelets. At 200 nM it stimulated the release of lysosomal hydrolases from large granule fractions of liver homogenate. It inhibited thromboxane synthesis in platelets, although it did not inhibit synthesis of prostacyclin in ram seminal vesicles. Thus, carbocyclic thromboxane A2, a molecule closely related to thromboxane A2, separates coronary vasoconstrictor from platelet-aggregating activity. The constrictor activity predominates in vivo; carbocyclic thromboxane A2 induces coronary vasoconstriction leading to myocardial ischemia and sudden death in rabbits in the absence of pulmonary or coronary thrombosis.

Full text

PDF
1706

Images in this article

1709Image
on p.1709

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bills T. K., Smith J. B., Silver M. J. Metabolism of [14C]arachidonic acid by human platelets. Biochim Biophys Acta. 1976 Feb 23;424(2):303–314. doi: 10.1016/0005-2760(76)90198-3. [DOI] [PubMed] [Google Scholar]
  2. Cottee F., Flower R. J., Moncada S., Salmon J. A., Vane J. R. Synthesis of 6-keto-PGF1alpha by ram seminal vesicle microsomes. Prostaglandins. 1977 Sep;14(3):413–423. doi: 10.1016/0090-6980(77)90257-x. [DOI] [PubMed] [Google Scholar]
  3. FOLCH J., LEES M., SLOANE STANLEY G. H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497–509. [PubMed] [Google Scholar]
  4. Gorman R. R. Modulation of human platelet function by prostacyclin and thromboxane A2. Fed Proc. 1979 Jan;38(1):83–88. [PubMed] [Google Scholar]
  5. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kluge A. F., Untch K. G., Fried J. H. Synthesis of prostaglandin models and prostaglandins by conjugate addition of a functionalized organocopper reagent. J Am Chem Soc. 1972 Nov 1;94(22):7827–7832. doi: 10.1021/ja00777a027. [DOI] [PubMed] [Google Scholar]
  7. Lefer A. M., Araki H., Smith J. B., Nicolaou K. C., Magolda R. L. Protective effects of a novel thromboxane analog in lethal traumatic shock. Prostaglandins Med. 1979 Sep;3(3):139–146. doi: 10.1016/0161-4630(79)90097-1. [DOI] [PubMed] [Google Scholar]
  8. Lefer A. M., Ogletree M. L., Smith J. B., Silver M. J., Nicolaou K. C., Barnette W. E., Gasic G. P. Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science. 1978 Apr 7;200(4337):52–54. doi: 10.1126/science.345441. [DOI] [PubMed] [Google Scholar]
  9. Needleman P., Minkes M., Raz A. Thromboxanes: selective biosynthesis and distinct biological properties. Science. 1976 Jul 9;193(4248):163–165. doi: 10.1126/science.945611. [DOI] [PubMed] [Google Scholar]
  10. Nicolaou K. C., Magolda R. L., Smith J. B., Aharony D., Smith E. F., Lefer A. M. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2566–2570. doi: 10.1073/pnas.76.6.2566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nugteren D. H., Hazelhof E. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta. 1973 Dec 20;326(3):448–461. doi: 10.1016/0005-2760(73)90145-8. [DOI] [PubMed] [Google Scholar]
  12. Ogletree M. L., Smith J. B., Lefer A. M. Actions of prostaglandins on isolated perfused cat coronary arteries. Am J Physiol. 1978 Oct;235(4):H400–H406. doi: 10.1152/ajpheart.1978.235.4.H400. [DOI] [PubMed] [Google Scholar]
  13. Schrör K., Smith E. F., 3rd, Bickerton M., Smith J. B., Nicolaou K. C., Magolda R., Lefer A. M. Preservation of ischemic myocardium by pinane thromboxane A2. Am J Physiol. 1980 Jan;238(1):H87–H92. doi: 10.1152/ajpheart.1980.238.1.H87. [DOI] [PubMed] [Google Scholar]
  14. Silver M. J., Hoch W., Kocsis J. J., Ingerman C. M., Smith J. B. Arachidonic acid causes sudden death in rabbits. Science. 1974 Mar 15;183(4129):1085–1087. doi: 10.1126/science.183.4129.1085. [DOI] [PubMed] [Google Scholar]
  15. Smith J. B., Ingerman C., Kocsis J. J., Silver M. J. Formation of prostaglandins during the aggregation of human blood platelets. J Clin Invest. 1973 Apr;52(4):965–969. doi: 10.1172/JCI107262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Terashita Z. I., Fukui H., Nishikawa K., Hirata M., Kikuchi S. Coronary vasospastic action of thromboxane A2 in isolated, working guinea pig hearts. Eur J Pharmacol. 1978 Dec 15;53(1):49–56. doi: 10.1016/0014-2999(78)90266-2. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES